Skip to main content
. 2020 Apr;26(4):667–674. doi: 10.3201/eid2604.191031

Table 3. Reported symptoms and illness severity of patients with shigellosis, by azithromycin susceptibility status and CD4 count, Minnesota, USA, 2012–2015*.

Characteristic DSA status, n = 691
CD4 count, cells/mm3, n = 878†
DSA, n = 46‡ Azithromycin susceptible, n = 64§ OR (95% CI)¶ p value <200, n = 6 200–500, n = 21 >500, n = 35 Not known to be PLWH, n = 816 p value
Bloody diarrhea 13 (35) 247 (45) 0.7 (0.3–1.3) 0.31 2 (50) 6 (46) 9 (33) 319 (46) 0.65
Fever 23 (66) 406 (74) 0.7 (0.3–1.4) 0.32 3 (75) 9 (69) 18 (69) 525 (75) 0.89
Hospitalized 8 (17) 136 (21) 0.8 (0.4–1.7) 0.71 3 (50) 8 (38) 13 (37) 143 (18) <0.001#
Death 0 1 (0) NA 1.00 0 0 0 1 (0) 0.99
Median illness duration, d (range) 11 (3–91) 9 (1–125) NA 0.004 7 (3–15) 11.5 (4–23) 11 (3–32) 8 (0–125) 0.03**

*Values are no. (%) unless otherwise indicated. DSA, decreased susceptibility to azithromycin; OR, odds ratio; NA, not applicable; PLWH, person living with HIV.
†Total number of infections was 882. However, CD4 count was not available for 4 PLWH.
‡Species distribution: Shigella sonnei, 52%; S. flexneri, 46%; S. boydii, 2%.
§Species distribution: S. sonnei, 83%; S. flexneri, 16%; S. boydii, 0.6%; S. dysenteriae, 0.3%.
¶Reference group is azithromycin-susceptible patients.
#Patients not known to be PLWH had lower hospitalization rates.
**Patients not known to be PLWH had shorter median duration of illness than PLWH with CD4 counts >200 cells/mm3.